Laurus Labs jumps on developing third-line HIV treatment for children

14 Sep 2021 Evaluate

Laurus Labs is currently trading at Rs. 655.85, up by 9.95 points or 1.54% from its previous closing of Rs. 645.90 on the BSE.

The scrip opened at Rs. 646.25 and has touched a high and low of Rs. 666.00 and Rs. 644.20 respectively. So far 221043 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 723.55 on 12-Aug-2021 and a 52 week low of Rs. 249.29 on 24-Sep-2020.

Last one week high and low of the scrip stood at Rs. 667.50 and Rs. 644.20 respectively. The current market cap of the company is Rs. 35201.12 crore.

The promoters holding in the company stood at 27.30%, while Institutions and Non-Institutions held 25.69% and 47.01% respectively.
 
Laurus Labs is developing a third-line HIV treatment, darunavir boosted with ritonavir (DRV/r), for children. The development is under way based on an agreement inked in June 2021 by the Hyderabad-based company, Unitaid and the Clinton Health Access Initiative (CHAI).

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

602.00 -0.35 (-0.06%)
01-Jan-2025 09:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1890.05
Dr. Reddys Lab 1378.10
Cipla 1522.65
Lupin 2345.00
Zydus Lifesciences 968.85
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.